Nerve Growth Factor (NGF)

Subscribe to Selected New Research on Nerve Growth Factor

3482 relevant articles (99 outcomes, 485 trials/studies) found for this Bio-Agent

Description: NERVE GROWTH FACTOR is the first of a series of neurotrophic factors that were found to influence the growth and differentiation of sympathetic and sensory neurons. It is comprised of alpha, beta, and gamma subunits. The beta subunit is responsible for its growth stimulating activity.

Also Known As:

NGF; NGF-1beta; beta-Nerve Growth Factor; Factor, beta-Nerve Growth; NGF 1beta; beta Nerve Growth Factor; Nerve Growth Factor 1; Nerve Growth Factor alpha Subunit; Nerve Growth Factor beta Subunit; Nerve Growth Factor gamma Subunit

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Peptides: 16375

Intercellular Signaling Peptides and Proteins: 9177

Nerve Growth Factors: 1298

Nerve Growth Factor: 3482

biotinylated nerve growth factor

human LIP1 proNGF peptide

human LIP2 proNGF peptide

human NGF protein

human pro-nerve growth factor

mouse pro-nerve growth factor

nerve growth factor (10-25,75-88)

nerve growth factor (75-88)

rat Lip2 protein

rat Retnla protein

Biological Factors: 931

Intercellular Signaling Peptides and Proteins: 9177

Nerve Growth Factors: 1298

Nerve Growth Factor: 3482

biotinylated nerve growth factor

human LIP1 proNGF peptide

human LIP2 proNGF peptide

human NGF protein

human pro-nerve growth factor

mouse pro-nerve growth factor

nerve growth factor (10-25,75-88)

nerve growth factor (75-88)

rat Lip2 protein

rat Retnla protein

Experts

1.	Aloe, Luigi: 26 articles (04/2008 - 03/2002)
2.	Aloe, L: 21 articles (03/2007 - 05/2000)
3.	Micera, Alessandra: 9 articles (04/2008 - 06/2002)
4.	Bonini, Stefano: 8 articles (04/2008 - 10/2003)
5.	Lambiase, Alessandro: 8 articles (04/2008 - 10/2003)
6.	Antonelli, Alessia: 7 articles (07/2008 - 04/2002)
7.	Hellweg, Rainer: 7 articles (02/2007 - 07/2002)
8.	Manni, L: 7 articles (10/2004 - 12/2000)
9.	Chiaretti, Antonio: 5 articles (07/2008 - 10/2005)
10.	Genovese, Orazio: 5 articles (07/2008 - 10/2005)

Related Diseases

1.	Pain (Aches) 09/12/2008 - "NGF antagonism is expected to be a highly effective and safe therapeutic approach in many pain states. " 11/01/2009 - "Patients who responded to treatment and had an improvement in VAS pain score of > or =2 had significantly lower NGF/Cr levels than nonresponders who had a VAS improvement of <2. CONCLUSIONS: Patients with IC/BPS had greater urinary NGF/Cr levels than controls. " 10/09/2001 - "Similar to their previously reported double-blind study, the authors showed that NGF was safe and well tolerated and significantly improved pain symptoms. " 02/01/2007 - "Therefore, our results suggest that NGF not only contributes to inflammatory pain but also governs the upregulation in the number and efficacy of sensory neuron MOR, resulting in enhanced opioid susceptibility towards better pain control. " 02/01/1999 - "However, anti-NGF but not NGF blocked collateral sprouting and decreased the severity of autotomy, suggesting that anti-NGF may be a better potential alternative analgesic for the treatment of neuropathic pain in humans. " Order ALL the reference details at left...
2.	Alzheimer Disease (Alzheimer's Disease) 04/01/1996 - "Since NGF-responsive basal forebrain cholinergic neurons are lost in Alzheimer's disease, treatment with NGF may be therapeutically beneficial for the patients with this disease. " 09/01/2005 - "But while NGF distinctly promoted neurite branching and elongation, Abeta was less effective in neurite elongation and counts of small processes and of growth cones remained clearly elevated after 24-h stimulation; these peculiarities might be linked to aberrant neuronal connections reported for an animal model of Alzheimer disease. " 04/13/1999 - "Effective NGF therapy required millimeter-scale positioning of the NGF source, and efficacy correlated with the spatial distribution of NGF concentration in the tissue; this result suggests that NGF must be delivered within several millimeters of the target to be effective in treating Alzheimer's disease. " 01/01/2009 - "These findings also support the safety and feasibility of lentiviral NGF gene transfer for potential testing in human clinical trials to protect degenerating cholinergic neurons in Alzheimer's disease." 07/01/2005 - "The role of nerve growth factor in stimulating cholinergic function, loss of which is a cardinal feature in Alzheimer's disease, has been documented for many years from preclinical animal model studies. " Order ALL the reference details at left...
3.	Hyperalgesia 01/16/2009 - "The present study addresses the question of whether EA can influence the hyperalgesia induced by NGF administration. " 01/01/2009 - "Many studies have focused on cutaneous mechanisms for NGF-induced hyperalgesia; few have examined its contribution in deeper tissues like muscle. " 01/01/2006 - "PERSPECTIVE: This study describes the development of a novel model of NGF-induced secondary hyperalgesia. " 11/01/1997 - "Although finding that NGF-induced hyperalgesia does not clearly correlate with changes in the release of SP-LI in the spinal cord, this study shows that NT-3 is an inhibitor of SP-LI release and suggests that this mechanism may be responsible for NT-3-induced antinociception." 01/01/2009 - "Our results indicate that the observed heat hyperalgesia is not dependent on NGF-induced changes in SP content and release from primary sensory neurons." Order ALL the reference details at left...
4.	Brain Injuries (Brain Injury) 11/01/1995 - "This study evaluated the neuroprotective efficacy of intracerebral NGF infusion after traumatic brain injury. " 07/01/2008 - "Nerve growth factor and doublecortin expression correlates with improved outcome in children with severe traumatic brain injury." 10/01/2005 - "CONCLUSION: Our observations are interesting, but further studies are necessary to confirm the effects of NGF in hypoxic-ischemic brain injuries in infants." 06/01/2005 - "These studies demonstrate for the first time that by increasing the brain concentration of NGF, intraventricularly transplanted MSCs might play an important role in the treatment of traumatic brain injury." 05/01/2008 - "Nerve growth factor expression correlates with severity and outcome of traumatic brain injury in children." Order ALL the reference details at left...
5.	Diabetic Neuropathies (Diabetic Neuropathy) 11/01/1994 - "These findings indicate that, while NGFR expression is normal in the STZ-diabetic neuropathy model, the marked decrease in receptor saturation observed in diabetics may reflect low peripheral NGF levels, which in consequence leads to the apparent deprivation of neuronal NGF in diabetic rats." 07/01/2002 - "These results suggest that gene transfer with an NGF-producing herpes-based vector may prove useful in the treatment of diabetic neuropathy." 11/01/1996 - "One study of NGF in patients with diabetic neuropathy found that the drug improved neurologic function and produced an increase in the patients' ability to sense cooling or painful heat. " 02/01/2003 - "However, a phase 3 trial in diabetic neuropathy and a phase 2 trial in HIV-related neuropathy have failed to demonstrate any substantial effect of treatment with NGF. " 01/01/2001 - "Recent studies have demonstrated that deficient NGF support of peptidergic nociceptors is involved in problems with small-fiber diabetic neuropathy. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Nerve Growth Factor (NGF)
2.	Brain-Derived Neurotrophic Factor (BDNF)
3.	Nerve Growth Factors (Neurotrophins)
4.	Antibodies
5.	Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)
6.	Messenger RNA (mRNA)
7.	Epidermal Growth Factor (EGF)
8.	Glial Cell Line-Derived Neurotrophic Factor (GDNF)
9.	Substance P
10.	Interleukin-1beta (Interleukin 1 beta)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Axotomy
3.	Transplantation (Transplant Recipients)
4.	Cell Transplantation
5.	Ligation

Best Treatments:
Research Summary Report
on Pain

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 9246 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>